Key result
Pharmacological agents that reduce both blood pressure and proteinuria, particularly ACE inhibitors, significantly slow the rate of progression of chronic kidney disease.
Why the study?
Does antihypertensive therapy, particularly ACE inhibitors, slow the progression of chronic kidney disease?
Does antihypertensive therapy, particularly ACE inhibitors, slow the progression of chronic kidney disease?
Answers are grounded in this paper and cite their sources.
ACE inhibitors provide a renoprotective effect that is additional to their blood pressure and proteinuria lowering effects in patients with chronic kidney disease.
Studies in animal models have shown a convincing role for hypertension in the progression of renal disease. However, in clinical studies, the relationship between hypertension and progression is difficult to demonstrate owing to confounding factors such as age, gender, race, difficulty in identifying blood pressure (BP) parameters that correlate with progression, abnormal circadian BP pattern, and many non-haemodynamic factors of progression. A recent meta-analysis of several studies has shown that pharmacological agents that reduce both BP and proteinuria (U(P)), particularly angiotensin-converting-enzyme (ACE) inhibitors, significantly slow the rate of progression of chronic kidney disease. In these studies, lower achieved BP in patients both with and without U(P) was associated with slower decline in renal function. ACE inhibitors are effective BP-lowering agents and are associated with improved preservation of renal function compared with antihypertensive regimens without ACE inhibitors. The protective effect of ACE inhibition is additional to the effect of reducing BP and U(P).
No takes yet. Share an insight, caveat, or question.
Maschio et al. (2002) conducted a review in Chronic renal disease. ACE inhibitors vs. Antihypertensive regimens without ACE inhibitors was evaluated on Progression of chronic kidney disease. Pharmacological agents that reduce both blood pressure and proteinuria, particularly ACE inhibitors, significantly slow the rate of progression of chronic kidney disease.
Synapse has enriched 10 related papers. Consider them for comparative context: